Advanced Imaging for Pulmonary Fibrosis

Last updated: March 24, 2025
Sponsor: Peter Caravan
Overall Status: Active - Recruiting

Phase

2

Condition

Pulmonary Fibrosis

Scar Tissue

Cystic Fibrosis

Treatment

Gadoterate Meglumine

[68Ga]CBP8

Clinical Study ID

NCT06532071
2024P001746
  • Ages 18-80
  • All Genders

Study Summary

The purpose of this study is to determine if measurements of active collagen deposition using [68Ga]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connectivetissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixedconnective tissue disease), or undifferentiated ILD.

  2. On stable dose immunosuppression treatment (with prednisone, mycophenolate mofetil,and/or rituximab) for at least 3 months.

  3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticularopacities on HRCT performed within 1 year to or at Visit 1.

  4. FVC of >/= 45% and DLCO >/= 25% predicted on PFTs performed at Visit 1.

Exclusion

Exclusion Criteria:

  1. Current or prior exposure to FDA approved anti-fibrotic therapy.

  2. Extent of emphysema greater than extent of fibrosis.

  3. Pregnancy or plans to become pregnant at baseline or during follow-up.

  4. Contraindications to MRI.

  5. Contraindications to receiving gadolinium-based contrast agents.

  6. Research-related radiation exposure exceeds 50 mSv in the prior year.

  7. Estimated glomerular filtration rate (eGFR) < 30 mL/min (only for individuals with ahistory of chronic kidney disease).

  8. Clinically significant PH defined by use of pulmonary vasodilatory therapy.

  9. Respiratory infection within the prior 6 weeks.

  10. Smoking of any kind within the prior 6 months.

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Gadoterate Meglumine
Phase: 2
Study Start date:
January 21, 2025
Estimated Completion Date:
December 31, 2028

Study Description

60 participants with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) on stable dose immunosuppression treatment will be enrolled. Participants will undergo combined [68Ga]CBP8 positron emission tomography (PET) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at baseline. The investigators will compare the ability of PET and MRI measurements performed over the whole lung and within regions of interest to identify participants who subsequently develop progressive pulmonary fibrosis as determined by changes in pulmonary function testing, quantitative fibrosis on high-resolution computed tomography, and respiratory symptoms over 24 months. The investigators will also test whether combining the PET and MRI measurements results in more accurate prediction of progression than either modality alone.

Connect with a study center

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.